Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors (Q58614658)
Jump to navigation
Jump to search
scientific article published on 06 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors |
scientific article published on 06 September 2011 |
Statements
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors (English)
Carlos Gomez-Roca
Jean-Pierre Delord
Andres Cervantes
Ben Markman
Jesus Corral
Jean-Charles Soria
Yann Bergé
Desamparados Roda
Fiona Russell-Yarde
Simon Hollingsworth
José Baselga
Pablo Umana
Luigi Manenti
Luis G Paz-Ares
6 September 2011